Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | VNN1 | O95497 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13010322 | 0.82 | SMN1; SMN2 (0.47) | EPHX2VNN1KCNH2CYP3A4ALDH1A1 | |
| SCHEMBL20469333 | 0.81 | EPHX2 (0.52) | EPHX2CYP3A4MGLL | |
| SCHEMBL4278413 | 0.79 | USP2 (0.54) | EPHX2MEN1KMT2AMGLLSMN1; SMN2 | |
| SCHEMBL368420 | 0.78 | VNN1 (0.40) | VNN1KCNH2CYP3A4ALDH1A1MEN1 | |
| SCHEMBL20469491 | 0.78 | EPHX2 (0.50) | EPHX2VNN1RIPK1MGLLSMN1; SMN2 | |
| SCHEMBL29317712 | 0.78 | EPHX2 (0.50) | EPHX2CYP3A4ALDH1A1HTTMGLL | |
| SCHEMBL13010536 | 0.77 | VNN1 (0.40) | VNN1KCNH2ALDH1A1MGLLCYP11B1 | |
| SCHEMBL2428734 | 0.77 | VNN1 (0.40) | VNN1KCNH2ALDH1A1HTTCYP11B1 | |
| SCHEMBL13328872 | 0.77 | KMT2A (0.50) | CYP3A4ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL27012796 | 0.76 | OPRM1 (0.39) | EPHX2VNN1KCNH2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | EPHX2 3114/4885VNN1 3710/4885KCNH2 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.